NASDAQ
114.42USD
-1.65 (-1.42%)
We have scored 9 news catalysts on BillionToOne, Inc. (BLLN) over the past 12 months. The biggest single-day move next to one of them came Mar 5, 2026, when BLLN closed −10.7%: “BillionToOne (BLLN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates”. Coverage across the window leans positive (average ticker sentiment +0.78). Most of the impact sits in price momentum and eps growth rate.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
5.3B
P/E
—
EPS
—
Beta
0.34
52W range
61.96-150.44
Day range
113.55–117.17
Open
116.00
Prev close
116.07
Volume
397.1K
Avg volume
728.8K
Dividend
0.00
IPO
2025-11-06
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about BillionToOne, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for BLLN: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.
